Skip to main content

Elevated Levels of Soluble Fibrin in Patients with Thrombosis or a Pre- Thrombotic State

Buy Article:

$63.00 plus tax (Refund Policy)


Background: Soluble fibrin (SF) is considered to be useful for the diagnosis of thrombosis, however, evidence for the diagnosis of pre-thrombosis by SF is still not well established.

Objective: The present study was designed to evaluate the usefulness of new SF assay (New SF) in the diagnosis of thrombosis and a pre-thrombotic state.

Patients/Methods: The plasma concentrations of New SF were measured in 748 inpatients suspected to have thrombosis and they correlated with thrombosis.

Results and Conclusions: The plasma concentrations of New SF were significantly higher in patients with disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT) and cerebral thrombosis, in comparison to those of patients without thrombosis, but there was no significant difference of the New SF assay between patients with thrombosis and those after an operation. The New SF assay was moderately correlated with the other two SF assays. The New SF levels were significantly higher in patients before the onset of thrombosis than in those without thrombosis but other hemostatic molecular markers were not significantly elevated. Our findings suggest that the New SF assay is useful for the diagnosis of not only thrombosis but also of a pre-thrombotic state.

Keywords: Pre-thrombotic state; deep vein thrombosis (DVT); disseminated intravascular coagulation (DIC); soluble fibrin (SF)

Document Type: Research Article


Publication date: November 1, 2008

More about this publication?
  • Vascular Disease Prevention publishes reviews as well as original papers to update all those concerned with this topic at the clinical or scientific level. In addition to clinically relevant topics, we consider reviews and original papers dealing with the more scientific aspects of vascular disease prevention. This includes the evaluation of emerging vascular risk factors, research dealing with the pathogenesis of atherosclerosis and the investigation of new treatment options both at the clinical and scientific level (e.g. epidemiology, patient-based studies, experimental models, in vitro experiments or molecular research). Therefore, another function of Vascular Disease Prevention is to bridge the gap between clinical practice and ongoing laboratory-based research.

    In particular, we welcome critical reviews and comments on recent trials. This is a topic that requires regular updates because of the large number of trials published every year.

    Debates are encouraged in the correspondence section of this journal.
    The editorial structure of Vascular Disease Prevention is set up with the aim of dealing with the submitted material as rapidly as possible. Specialist editors will provide a more expert and rapid assessment unlike a more centralized editorial structure.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more
Real Time Web Analytics